Establishment of a Lysosome-related Prognostic Signature in Breast Cancer to Predict Immune Infiltration and Therapy Response

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Jan 1

PMID 38162504

Authors

Hairong Su

Ying Chen

Fengye Lin

Wanhua Li

Xiangyu Gu

Weijie Zeng

Dan Liu

Man Li

Shaowen Zhong

Qianjun Chen

Qubo Chen

Affiliations

Soon will be listed here.

Abstract

Background: Lysosomes are instrumental in intracellular degradation and recycling, with their functional alterations holding significance in tumor growth. Nevertheless, the precise role of lysosome-related genes (LRGs) in breast cancer (BC) remains elucidated. This study aimed to establish a prognostic model for BC based on LRGs.

Methods: Employing The Cancer Genome Atlas (TCGA) BC cohort as a training dataset, this study identified differentially expressed lysosome-related genes (DLRGs) through intersecting LRGs with differential expression genes (DEGs) between tumor and normal samples. A prognostic model of BC was subsequently developed using Cox regression analysis and validated within two Gene Expression Omnibus (GEO) external validation sets. Further analyses explored functional pathways, the immune microenvironment, immunotherapeutic responses, and sensitivity to chemotherapeutic drugs in different risk groups. Additionally, the mRNA and protein expression levels of genes within the risk model were examined by utilizing the Gene Expression Profiling Interactive Analysis (GEPIA) and Human Protein Atlas (HPA) databases. Clinical tissue specimens obtained from patients were gathered to validate the expression of the model genes via Real-Time Polymerase Chain Reaction (RT-PCR).

Results: We developed a risk model of BC based on five specific genes (ATP6AP1, SLC7A5, EPDR1, SDC1, and PIGR). The model was validated for overall survival (OS) in two GEO validation sets (=0.00034 for GSE20685 and =0.0095 for GSE58812). In addition, the nomogram incorporating clinical factors showed better predictive performance. Compared to the low-risk group, the high-risk group had a higher level of certain immune cell infiltration, including regulatory T cells (Tregs) and type 2 T helper cells (Th2). The high-risk patients appeared to respond less well to general immunotherapy and chemotherapeutic drugs, according to the Tumor Immune Dysfunction and Exclusion (TIDE), Immunophenotype Score (IPS), and drug sensitivity scores. The RT-PCR results validated the expression trends of some prognostic-related genes in agreement with the previous differential expression analysis.

Conclusion: Our innovative lysosome-associated signature can predict the prognosis for BC patients, offering insights for guiding subsequent immunotherapeutic and chemotherapeutic interventions. Furthermore, it has the potential to provide a scientific foundation for identifying prospective therapeutic targets.

Citing Articles

Predicting ipsilateral supraclavicular lymph node pathological complete response: nomogram based on the inflammatory markers.

Zhou C, Wu X, Lin R, Xu L, He T, Yi J Front Oncol. 2024; 14:1412607.

PMID: 39588307 PMC: 11586358. DOI: 10.3389/fonc.2024.1412607.

References

Asanprakit W, Lobo D, Eremin O, Bennett A . M1 macrophages evoke an increase in polymeric immunoglobulin receptor (PIGR) expression in MDA-MB468 breast cancer cells through secretion of interleukin-1β. Sci Rep. 2022; 12(1):16842. PMC: 9546936. DOI: 10.1038/s41598-022-20811-6. View

Wang Y, Chen Y, Gao G, Zheng Y, Yu N, Ouyang L . Polyphyllin D punctures hypertrophic lysosomes to reverse drug resistance of hepatocellular carcinoma by targeting acid sphingomyelinase. Mol Ther. 2023; 31(7):2169-2187. PMC: 10362416. DOI: 10.1016/j.ymthe.2023.05.015. View

Dong M, Cui X, Wang G, Zhang Q, Li X . Development of a prognostic signature based on immune-related genes and the correlation with immune microenvironment in breast cancer. Aging (Albany NY). 2022; 14(13):5427-5448. PMC: 9320535. DOI: 10.18632/aging.204158. View

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X . Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018; 24(10):1550-1558. PMC: 6487502. DOI: 10.1038/s41591-018-0136-1. View

James L, Georgopoulos A . Immunogenetic clustering of 30 cancers. Sci Rep. 2022; 12(1):7235. PMC: 9068692. DOI: 10.1038/s41598-022-11366-7. View

Luzio J, Pryor P, Bright N . Lysosomes: fusion and function. Nat Rev Mol Cell Biol. 2007; 8(8):622-32. DOI: 10.1038/nrm2217. View

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

Bonam S, Wang F, Muller S . Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019; 18(12):923-948. PMC: 7097195. DOI: 10.1038/s41573-019-0036-1. View

Cao M, Luo X, Wu K, He X . Targeting lysosomes in human disease: from basic research to clinical applications. Signal Transduct Target Ther. 2021; 6(1):379. PMC: 8572923. DOI: 10.1038/s41392-021-00778-y. View

10.

Latifkar A, Ling L, Hingorani A, Johansen E, Clement A, Zhang X . Loss of Sirtuin 1 Alters the Secretome of Breast Cancer Cells by Impairing Lysosomal Integrity. Dev Cell. 2019; 49(3):393-408.e7. PMC: 6519475. DOI: 10.1016/j.devcel.2019.03.011. View

11.

Hu M, Chong R, Liu W, Liu S, Liu X . Characteristic of molecular subtype based on lysosome-associated genes reveals clinical prognosis and immune infiltration of gastric cancer. Front Oncol. 2023; 13:1155418. PMC: 10183605. DOI: 10.3389/fonc.2023.1155418. View

12.

Abdulla M, Valli-Mohammed M, Al-Khayal K, Al Shkieh A, Zubaidi A, Ahmad R . Cathepsin B expression in colorectal cancer in a Middle East population: Potential value as a tumor biomarker for late disease stages. Oncol Rep. 2017; 37(6):3175-3180. PMC: 5442396. DOI: 10.3892/or.2017.5576. View

13.

Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R . Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discov. 2017; 7(12):1420-1435. PMC: 5718941. DOI: 10.1158/2159-8290.CD-17-0593. View

14.

Carbo J, Cornet-Masana J, Cuesta-Casanovas L, Delgado-Martinez J, Banus-Mulet A, Clement-Demange L . A Novel Family of Lysosomotropic Tetracyclic Compounds for Treating Leukemia. Cancers (Basel). 2023; 15(6). PMC: 10047683. DOI: 10.3390/cancers15061912. View

15.

Yang Y, Xu H, Zhu H, Yuan D, Zhang H, Liu Z . EPDR1 levels and tumor budding predict and affect the prognosis of bladder carcinoma. Front Oncol. 2022; 12:986006. PMC: 9585273. DOI: 10.3389/fonc.2022.986006. View

16.

Riaz N, Havel J, Makarov V, Desrichard A, Urba W, Sims J . Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017; 171(4):934-949.e16. PMC: 5685550. DOI: 10.1016/j.cell.2017.09.028. View

17.

Aits S, Jaattela M . Lysosomal cell death at a glance. J Cell Sci. 2013; 126(Pt 9):1905-12. DOI: 10.1242/jcs.091181. View

18.

Trayes K, Cokenakes S . Breast Cancer Treatment. Am Fam Physician. 2021; 104(2):171-178. View

19.

Karagounis I, Kalamida D, Mitrakas A, Pouliliou S, Liousia M, Giatromanolaki A . Repression of the autophagic response sensitises lung cancer cells to radiation and chemotherapy. Br J Cancer. 2016; 115(3):312-21. PMC: 4973160. DOI: 10.1038/bjc.2016.202. View

20.

di Francia R, Crisci S, De Monaco A, Cafiero C, Re A, Iaccarino G . Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers. Cancers (Basel). 2021; 13(5). PMC: 7956511. DOI: 10.3390/cancers13050966. View